Gene therapy with recombinant Sendai virus vector for peripheral arterial disease: 1-year follow-up of QOL scores

Tanaka M.; Imamura M.; Yoshida K.; Yonemitsu Y.

首页> 外文期刊>Human gene therapy >Gene therapy with recombinant Sendai virus vector for peripheral arterial disease: 1-year follow-up of QOL scores

【24h】

Gene therapy with recombinant Sendai virus vector for peripheral arterial disease: 1-year follow-up of QOL scores

机译：重组仙台病毒载体对外周动脉疾病的基因治疗：QOL评分的1年随访

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Human gene therapy》 |2016年第11期|共1页
作者
Tanaka M.; Imamura M.; Yoshida K.; Yonemitsu Y.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词

相似文献

外文文献
中文文献
专利

1. Gene therapy with recombinant Sendai virus vector for peripheral arterial disease: 1-year follow-up of QOL scores [J] . Tanaka M., Imamura M., Yoshida K., Human gene therapy . 2016,第11期

机译：重组仙台病毒载体对外周动脉疾病的基因治疗：QOL评分的1年随访
2. Recombinant Sendai virus (rSeV) as a cytoplasmic vector for human gene therapy and RNA vaccine [J] . Yoshikazu Yonemitsu Experimental Animals . 2008,第3supa期

机译：重组仙台病毒（rSeV）作为用于人类基因治疗和RNA疫苗的细胞质载体
3. Generation of a recombinant Newcastle disease virus expressing two foreign genes for use as a multivalent vaccine and gene therapy vector [J] . Hu Haixia, Roth Jason P., Yu Qingzhong Vaccine . 2018,第32aPta2期

机译：生成表达两种外源基因的重组新城疫病毒用作多价疫苗和基因治疗载体
4. Construction of Recombinant Rabbit Hemorrhagic Disease Virus (RHDV) Vaccine Using Myxoma Virus (MV) as a Vector [C] . Guo Zhen, Wang Yuan, Yu Qian, 5th International Conference on Bioinformatics and Biomedical Engineering . 2011

机译：以粘液瘤病毒（MV）为载体构建重组兔失血性疾病病毒（RHDV）疫苗
5. Efficacy of a recombinant herpes virus of turkeys vector vaccine, expressing genes to Newcastle disease virus and Marek's disease virus, in chickens and turkeys against exotic Newcastle disease virus challenge. [D] . Heskett, Eric A. 2003

机译：在鸡和火鸡中表达重组新城疫病毒和马立克氏病病毒基因的火鸡载体疫苗重组疱疹病毒抵抗外来新城疫病毒挑战的功效。
6. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation but not with high-capacity adenovirus vectors: Toward realistic long-term neurological gene therapy for chronic diseases [O] . Clare E. Thomas, Gudrun Schiedner, Stefan Kochanek, 2000

机译：腺病毒的周边感染在第一代颅内注射动物的动物中引起意料之外的长期脑部炎症但不向大容量腺病毒载体注射动物：朝着对慢性疾病进行现实的长期神经基因治疗
7. 103. Phase I/IIa, Open-Labeled, Dose Escalation Clinical Study Using DVC1-0101 (F-Gene-Deleted Non-Transmissible Recombinant Sendai Virus Vector Expressing Human FGF-2) To Treat Peripheral Arterial Disease [O] . 2011

机译：103.使用DVC1-0101（F-Gene-Deleted的非传染性重组仙台病毒载体，表达人FGF-2的F-Gene-Deletible重组仙台病毒载体的临床临床研究，inse / Iia，Ops-Lableded，剂量升级临床研究以治疗外周动脉疾病
8. Guidance for Industry. Supplemental Guidance on Testing for Replication Compentent Retrovirus in Retroviral Vector Based Gene Therapy Products and During Follow-up of Patients in Clinical Trials Using Retroviral Vectors. [R] . 2000

机译：工业指南。基于逆转录病毒载体的基因治疗产品和临床试验患者随访期间使用逆转录病毒载体检测复制耐受性逆转录病毒的补充指南。

Gene therapy with recombinant Sendai virus vector for peripheral arterial disease: 1-year follow-up of QOL scores

著录项

相似文献

相关主题

期刊订阅